data_5j6v_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5j6v _Structure_validation_residue.Date_analyzed 2017-04-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.422 ' HB3' ' CE2' ' A' ' 3' ' ' PHE . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.111 0.482 . . . . 0.0 110.153 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 12.3 mt -79.08 76.35 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 110.121 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' A' ' 1' ' ' ASP . 36.4 m-85 -120.74 18.59 11.9 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.323 -0.861 . . . . 0.0 110.344 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.35 -38.88 0.57 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -76.81 -30.61 56.49 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.36 -1.082 . . . . 0.0 110.264 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -78.38 -5.23 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.395 -0.816 . . . . 0.0 110.443 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.533 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.54 -55.54 0.86 Allowed Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.137 -0.977 . . . . 0.0 110.102 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.533 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 32.2 Cg_exo -55.65 -27.76 62.41 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.382 1.201 . . . . 0.0 110.271 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.97 -59.24 3.04 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.411 -0.805 . . . . 0.0 110.145 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.85 -33.49 66.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.306 -0.871 . . . . 0.0 109.972 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 65.4 mt -69.11 -40.63 78.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.468 -0.77 . . . . 0.0 109.811 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.91 -24.16 75.76 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.88 -42.66 48.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.382 -1.069 . . . . 0.0 109.49 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.7 mt -69.97 -19.61 63.35 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.503 -0.748 . . . . 0.0 109.925 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.42 -50.06 13.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.274 -0.891 . . . . 0.0 109.977 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -64.8 -14.0 57.55 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.327 -0.858 . . . . 0.0 110.0 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.403 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 16.7 tp -70.12 -60.62 2.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.316 -0.865 . . . . 0.0 109.983 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.403 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 31.0 pt -137.04 26.51 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.331 -0.856 . . . . 0.0 110.042 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -134.03 174.35 10.58 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.343 -0.848 . . . . 0.0 110.142 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 O-C-N 119.816 -1.803 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.159 0.504 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 91.3 mt -67.03 -27.37 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.375 -0.828 . . . . 0.0 110.135 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -105.06 30.05 5.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.417 -0.802 . . . . 0.0 109.981 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -145.87 -37.79 0.06 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.71 27.59 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.202 -1.175 . . . . 0.0 110.347 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.21 -3.56 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.381 -0.825 . . . . 0.0 110.592 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.548 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -85.61 -54.58 0.42 Allowed Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.12 -0.988 . . . . 0.0 110.281 -179.794 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.548 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 23.7 Cg_exo -58.68 -27.88 84.62 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 O-C-N 123.432 1.227 . . . . 0.0 110.297 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.9 tp -72.18 -59.11 2.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.417 -0.802 . . . . 0.0 110.33 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.76 -32.54 65.7 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.342 -0.849 . . . . 0.0 110.221 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 96.4 mt -72.49 -38.68 68.08 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.443 -0.786 . . . . 0.0 109.996 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.77 -23.19 78.08 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.7 -42.16 29.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.391 -1.064 . . . . 0.0 109.598 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.2 mt -75.9 -16.98 59.94 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.556 -0.715 . . . . 0.0 110.021 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 14.5 ttpt -82.21 -46.36 13.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 110.073 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -66.09 -13.57 60.28 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -0.847 . . . . 0.0 110.149 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.418 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 15.1 tp -72.11 -60.86 2.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.871 . . . . 0.0 110.006 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 32.0 pt -136.34 26.76 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.236 -0.915 . . . . 0.0 110.154 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 10.9 mttm -134.57 100.39 4.63 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.184 -179.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.277 0 O-C-N 119.819 -1.801 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.2 t0 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.2 0.524 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -141.26 55.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.34 -0.85 . . . . 0.0 109.963 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -126.24 10.42 7.43 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.435 -0.791 . . . . 0.0 110.32 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.491 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -114.17 -10.77 13.15 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.94 -44.39 9.93 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.162 -1.199 . . . . 0.0 110.232 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.63 -16.64 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.365 -0.834 . . . . 0.0 110.4 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.509 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -68.64 -53.29 16.6 Favored Pre-proline 0 N--CA 1.494 1.757 0 O-C-N 121.147 -0.971 . . . . 0.0 110.416 -179.885 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.509 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 26.5 Cg_exo -57.18 -28.84 81.15 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 123.392 1.207 . . . . 0.0 110.198 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.3 tp -68.2 -55.22 13.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.47 -0.769 . . . . 0.0 109.87 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.05 -36.14 70.15 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.294 -0.879 . . . . 0.0 109.862 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.46 -43.11 86.42 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.561 -0.712 . . . . 0.0 109.688 179.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.86 -26.2 71.07 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.73 -43.7 53.67 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.43 -1.041 . . . . 0.0 109.461 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 84.6 mt -69.25 -19.78 63.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.431 -0.793 . . . . 0.0 109.856 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.404 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 35.5 ttpt -81.11 -45.18 16.85 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 0.0 109.996 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -67.01 -13.19 61.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.392 -0.817 . . . . 0.0 110.169 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.407 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 13.6 tp -72.69 -60.49 2.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.283 -0.886 . . . . 0.0 110.004 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.407 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 29.4 pt -136.14 24.79 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.341 -0.849 . . . . 0.0 110.239 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.404 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 9.8 mttt -133.04 12.18 4.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.321 -0.862 . . . . 0.0 110.339 -179.367 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.321 0 O-C-N 119.699 -1.875 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 16.0 t70 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.211 0.529 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.5 tp -153.75 57.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.285 -0.885 . . . . 0.0 110.134 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -125.76 -30.56 3.02 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.34 -0.85 . . . . 0.0 110.333 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.478 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -70.99 -19.58 77.21 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.34 -40.76 12.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.182 -1.187 . . . . 0.0 110.341 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 3.5 tt -79.09 -10.55 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.378 -0.826 . . . . 0.0 110.578 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.514 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -76.11 -54.1 2.11 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.113 -0.992 . . . . 0.0 110.191 -179.945 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.514 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 37.7 Cg_exo -55.46 -26.83 55.84 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 O-C-N 123.375 1.197 . . . . 0.0 110.317 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.57 -56.3 7.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.378 -0.826 . . . . 0.0 110.108 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.84 -33.02 69.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.41 -0.807 . . . . 0.0 109.856 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 95.1 mt -69.68 -39.83 76.76 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.494 -0.754 . . . . 0.0 109.715 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.77 -25.02 74.22 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.196 -1.561 . . . . 0.0 109.196 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -77.12 -40.7 44.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.382 -1.069 . . . . 0.0 109.529 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 92.2 mt -76.02 -15.04 60.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.522 -0.736 . . . . 0.0 110.078 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.99 -50.67 11.69 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.363 -0.835 . . . . 0.0 110.172 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -64.69 -11.91 40.89 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.337 -0.852 . . . . 0.0 110.227 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.41 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 11.3 tp -72.68 -59.03 2.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 110.023 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.41 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 29.1 pt -137.9 22.77 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.35 -0.844 . . . . 0.0 110.21 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.0 mtmt -128.77 52.5 1.93 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.33 -0.856 . . . . 0.0 110.223 -179.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.361 0 O-C-N 119.843 -1.786 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.465 ' HB2' ' CE2' ' A' ' 3' ' ' PHE . 11.0 p-10 . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 121.244 0.545 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 47.9 mm -124.06 93.42 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.111 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.465 ' CE2' ' HB2' ' A' ' 1' ' ' ASP . 12.1 m-85 -126.1 1.37 7.2 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.3 -0.875 . . . . 0.0 110.485 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -113.52 -33.0 1.99 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 -27.59 60.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -1.063 . . . . 0.0 110.393 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.1 tt -78.95 -1.96 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.606 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.545 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -85.08 -54.76 0.43 Allowed Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.187 -0.946 . . . . 0.0 110.115 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.545 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 27.5 Cg_exo -57.0 -27.98 76.18 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.499 1.263 . . . . 0.0 110.193 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.9 tp -68.15 -55.73 11.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.42 -0.8 . . . . 0.0 110.025 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.15 -35.56 69.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.285 -0.884 . . . . 0.0 110.015 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 91.6 mt -68.05 -41.77 81.54 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.467 -0.771 . . . . 0.0 109.893 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.32 -24.68 73.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -77.0 -39.21 51.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.416 -1.049 . . . . 0.0 109.395 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.5 mt -70.08 -17.82 63.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.56 -0.713 . . . . 0.0 110.029 179.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 1.2 ttpt -82.62 -44.57 15.63 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.296 -0.878 . . . . 0.0 110.207 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -71.76 -6.19 39.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.329 -0.857 . . . . 0.0 110.086 179.445 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.406 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 9.0 tp -78.95 -57.92 3.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.317 -0.864 . . . . 0.0 109.95 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.406 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 28.0 pt -138.19 22.8 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.322 -0.861 . . . . 0.0 110.192 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -130.99 50.07 2.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 -179.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.369 0 O-C-N 119.86 -1.775 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.451 ' CB ' ' CE1' ' A' ' 3' ' ' PHE . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.148 0.499 . . . . 0.0 110.081 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 5.2 mp -94.69 45.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.278 -0.889 . . . . 0.0 110.24 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.451 ' CE1' ' CB ' ' A' ' 1' ' ' ASP . 24.8 m-85 -95.05 90.86 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.274 -0.891 . . . . 0.0 110.112 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.474 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . 146.17 -30.2 1.62 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.93 -33.12 13.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.431 -1.041 . . . . 0.0 110.021 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.0 tt -70.3 -12.08 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.483 -0.761 . . . . 0.0 110.53 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.512 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -86.27 -56.95 0.35 Allowed Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.164 -0.96 . . . . 0.0 110.35 -179.876 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.512 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 39.2 Cg_exo -51.8 -27.16 26.14 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.31 1.163 . . . . 0.0 110.46 179.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -66.79 -57.28 7.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.377 -0.827 . . . . 0.0 110.031 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.22 -36.9 71.45 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.329 -0.857 . . . . 0.0 110.043 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 94.7 mt -64.67 -42.2 95.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.567 -0.708 . . . . 0.0 109.815 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.03 -23.23 76.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.72 -41.16 54.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.378 -1.072 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 49.7 mt -69.93 -19.94 63.36 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.429 -0.795 . . . . 0.0 109.747 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.417 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 25.8 ttpt -81.24 -41.13 22.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.31 -0.869 . . . . 0.0 109.913 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -73.18 -5.69 40.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.331 -0.856 . . . . 0.0 110.08 179.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.418 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 5.7 tp -80.67 -56.68 3.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.323 -0.861 . . . . 0.0 109.909 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 26.4 pt -137.29 17.04 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.35 -0.844 . . . . 0.0 110.416 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.417 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -125.29 -157.03 0.76 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.261 -0.899 . . . . 0.0 110.091 -179.636 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.331 0 O-C-N 119.805 -1.81 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.228 0.537 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.414 ' O ' ' CD1' ' A' ' 3' ' ' PHE . 2.1 tp -157.95 68.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.382 -0.824 . . . . 0.0 110.083 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.414 ' CD1' ' O ' ' A' ' 2' ' ' ILE . 31.9 m-85 -138.09 -43.92 0.51 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.332 -0.855 . . . . 0.0 110.187 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -109.68 10.33 32.55 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.33 -50.32 5.71 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.255 -1.144 . . . . 0.0 110.109 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.9 tt -71.58 -22.25 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.85 . . . . 0.0 110.156 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.524 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 m0 -63.74 -58.36 15.35 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.385 -0.822 . . . . 0.0 110.413 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 4.0 Cg_endo -54.56 -36.25 88.4 Favored 'Trans proline' 0 C--N 1.315 -1.222 0 O-C-N 123.426 1.224 . . . . 0.0 111.008 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.0 tt -68.4 -54.5 16.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -37.74 71.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.145 -0.972 . . . . 0.0 110.077 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 61.6 mt -67.32 -40.98 85.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.619 -0.676 . . . . 0.0 109.751 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.28 -25.45 72.41 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.68 -41.44 45.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.309 -1.113 . . . . 0.0 109.592 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 90.9 mt -74.99 -15.76 60.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.495 -0.753 . . . . 0.0 110.094 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.58 -50.73 7.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.87 . . . . 0.0 110.183 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -65.18 -13.3 57.87 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.371 -0.831 . . . . 0.0 110.188 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.41 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 13.5 tp -72.16 -59.5 2.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 110.088 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.41 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 29.5 pt -137.25 27.08 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.286 -0.884 . . . . 0.0 110.178 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -134.79 48.69 2.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.326 -0.859 . . . . 0.0 110.205 -179.241 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.383 0 O-C-N 119.853 -1.779 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.227 0.537 . . . . 0.0 110.187 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.8 tt -149.72 64.68 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.322 -0.861 . . . . 0.0 110.088 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -134.32 -43.83 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.402 -0.811 . . . . 0.0 109.997 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.477 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -76.95 -17.46 79.8 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.94 -40.14 14.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.245 -1.15 . . . . 0.0 110.287 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.1 tp -80.06 -11.89 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -0.85 . . . . 0.0 110.385 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.525 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -72.95 -54.12 4.75 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.181 -0.949 . . . . 0.0 110.316 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.525 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 25.2 Cg_exo -56.94 -27.85 74.98 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.4 1.211 . . . . 0.0 110.264 179.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -69.87 -52.27 26.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.465 -0.772 . . . . 0.0 110.057 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.95 -31.69 71.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.35 -0.844 . . . . 0.0 110.003 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 98.4 mt -73.11 -38.92 66.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.436 -0.79 . . . . 0.0 109.89 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.28 -23.08 78.46 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.37 -40.85 29.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.295 -1.12 . . . . 0.0 109.458 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.1 mt -75.9 -15.64 60.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.475 -0.766 . . . . 0.0 110.171 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -78.88 -52.48 8.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.188 -0.945 . . . . 0.0 110.098 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -65.43 -12.13 49.44 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.257 -0.902 . . . . 0.0 110.225 179.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.427 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 10.4 tp -73.96 -58.39 3.33 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.307 -0.871 . . . . 0.0 110.057 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.427 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 32.2 pt -137.29 25.59 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.327 -0.858 . . . . 0.0 110.34 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.0 mtpt -132.78 24.27 4.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.174 -179.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.295 0 O-C-N 119.775 -1.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 24.2 p30 . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 121.207 0.527 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.1 mm -114.96 -17.44 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.371 -0.83 . . . . 0.0 110.458 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -109.76 -13.48 14.48 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.316 -0.865 . . . . 0.0 110.423 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.484 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -113.55 2.94 24.85 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.14 -43.23 10.01 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.11 -1.229 . . . . 0.0 110.259 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -78.73 -15.09 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 110.468 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.512 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -71.7 -54.37 6.48 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.117 -0.989 . . . . 0.0 110.385 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.512 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 38.9 Cg_exo -54.89 -27.36 53.14 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.387 1.204 . . . . 0.0 110.432 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.15 -58.56 4.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.445 -0.784 . . . . 0.0 110.252 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.01 -37.46 69.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.26 -0.9 . . . . 0.0 110.078 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.4 mt -65.73 -41.22 92.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.527 -0.733 . . . . 0.0 109.856 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.56 -24.49 73.89 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.23 -40.76 51.29 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.359 -1.083 . . . . 0.0 109.698 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.0 mt -76.49 -14.9 60.01 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -76.85 -48.86 17.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.197 -0.939 . . . . 0.0 110.185 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -64.94 -13.52 57.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.284 -0.885 . . . . 0.0 110.171 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.418 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 13.8 tp -71.08 -60.5 2.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.864 . . . . 0.0 110.007 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 30.3 pt -136.85 24.12 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.337 -0.852 . . . . 0.0 110.106 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.18 24.55 4.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.372 -0.83 . . . . 0.0 110.195 -179.368 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.355 0 O-C-N 119.894 -1.754 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.3 t70 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.126 0.489 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.441 HG22 HD11 ' A' ' 2' ' ' ILE . 83.5 mt -134.86 10.44 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 110.397 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -126.93 3.06 6.59 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.305 -0.872 . . . . 0.0 110.262 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.47 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -113.46 -22.38 5.49 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.17 -35.94 15.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.218 -1.166 . . . . 0.0 110.259 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.5 tt -79.02 -7.31 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.378 -0.826 . . . . 0.0 110.614 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.536 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -82.03 -53.83 0.67 Allowed Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.104 -0.997 . . . . 0.0 110.301 -179.929 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.536 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 34.5 Cg_exo -56.62 -26.54 65.38 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.45 1.237 . . . . 0.0 110.244 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.4 tp -70.31 -64.38 0.9 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.551 -0.718 . . . . 0.0 110.308 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.47 -32.65 62.99 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.278 -0.889 . . . . 0.0 110.13 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 67.8 mt -69.37 -38.58 78.12 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.429 -0.795 . . . . 0.0 109.875 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.4 -23.81 77.21 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.26 -42.69 44.86 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.441 -1.035 . . . . 0.0 109.492 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 91.9 mt -68.32 -20.53 64.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.578 -0.701 . . . . 0.0 109.903 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.418 ' N ' ' CE ' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -87.4 -30.44 20.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.769 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -81.84 1.12 36.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.462 -0.774 . . . . 0.0 110.014 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.431 ' HG ' ' CG2' ' A' ' 18' ' ' ILE . 4.3 tp -91.31 -56.57 3.09 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.279 -0.888 . . . . 0.0 109.901 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.431 ' CG2' ' HG ' ' A' ' 17' ' ' LEU . 26.3 pt -136.27 27.31 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.297 -0.877 . . . . 0.0 110.366 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.403 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 13.2 mttt -137.38 173.59 11.5 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.281 -0.887 . . . . 0.0 110.128 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.34 0 O-C-N 119.786 -1.821 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.448 ' HB3' ' CE2' ' A' ' 3' ' ' PHE . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.111 0.482 . . . . 0.0 110.153 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 12.3 mt -79.08 76.35 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 110.121 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.448 ' CE2' ' HB3' ' A' ' 1' ' ' ASP . 36.4 m-85 -120.74 18.59 11.9 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.323 -0.861 . . . . 0.0 110.344 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.408 ' O ' ' HD3' ' A' ' 8' ' ' PRO . . . -122.35 -38.88 0.57 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -76.81 -30.61 56.49 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.36 -1.082 . . . . 0.0 110.264 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -78.38 -5.23 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.395 -0.816 . . . . 0.0 110.443 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.548 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.54 -55.54 0.86 Allowed Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.137 -0.977 . . . . 0.0 110.102 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.548 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 32.2 Cg_exo -55.65 -27.76 62.41 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.382 1.201 . . . . 0.0 110.271 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.97 -59.24 3.04 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.411 -0.805 . . . . 0.0 110.145 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.85 -33.49 66.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.306 -0.871 . . . . 0.0 109.972 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 65.4 mt -69.11 -40.63 78.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.468 -0.77 . . . . 0.0 109.811 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.91 -24.16 75.76 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.88 -42.66 48.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.382 -1.069 . . . . 0.0 109.49 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.7 mt -69.97 -19.61 63.35 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.503 -0.748 . . . . 0.0 109.925 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.407 ' HA ' ' CG ' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -77.42 -50.06 13.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.274 -0.891 . . . . 0.0 109.977 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -64.8 -14.0 57.55 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.327 -0.858 . . . . 0.0 110.0 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.909 ' HG ' HG23 ' A' ' 18' ' ' ILE . 16.7 tp -70.12 -60.62 2.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.316 -0.865 . . . . 0.0 109.983 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.909 HG23 ' HG ' ' A' ' 17' ' ' LEU . 31.0 pt -137.04 26.51 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.331 -0.856 . . . . 0.0 110.042 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.407 ' CG ' ' HA ' ' A' ' 15' ' ' LYS . 7.9 mttm -134.03 174.35 10.58 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.343 -0.848 . . . . 0.0 110.142 -179.279 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 O-C-N 119.816 -1.803 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.159 0.504 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 91.3 mt -67.03 -27.37 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.375 -0.828 . . . . 0.0 110.135 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -105.06 30.05 5.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.417 -0.802 . . . . 0.0 109.981 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -145.87 -37.79 0.06 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.71 27.59 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.202 -1.175 . . . . 0.0 110.347 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.21 -3.56 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.381 -0.825 . . . . 0.0 110.592 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.553 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -85.61 -54.58 0.42 Allowed Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.12 -0.988 . . . . 0.0 110.281 -179.794 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.553 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 23.7 Cg_exo -58.68 -27.88 84.62 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 O-C-N 123.432 1.227 . . . . 0.0 110.297 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.9 tp -72.18 -59.11 2.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.417 -0.802 . . . . 0.0 110.33 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.76 -32.54 65.7 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.342 -0.849 . . . . 0.0 110.221 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 96.4 mt -72.49 -38.68 68.08 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.443 -0.786 . . . . 0.0 109.996 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.77 -23.19 78.08 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.7 -42.16 29.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.391 -1.064 . . . . 0.0 109.598 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.2 mt -75.9 -16.98 59.94 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.556 -0.715 . . . . 0.0 110.021 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.447 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 14.5 ttpt -82.21 -46.36 13.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 110.073 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -66.09 -13.57 60.28 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -0.847 . . . . 0.0 110.149 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.906 ' HG ' HG23 ' A' ' 18' ' ' ILE . 15.1 tp -72.11 -60.86 2.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.871 . . . . 0.0 110.006 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.906 HG23 ' HG ' ' A' ' 17' ' ' LEU . 32.0 pt -136.34 26.76 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.236 -0.915 . . . . 0.0 110.154 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 10.9 mttm -134.57 100.39 4.63 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.184 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.277 0 O-C-N 119.819 -1.801 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.2 t0 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.2 0.524 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.508 ' O ' HG23 ' A' ' 2' ' ' ILE . 1.0 OUTLIER -141.26 55.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.34 -0.85 . . . . 0.0 109.963 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -126.24 10.42 7.43 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.435 -0.791 . . . . 0.0 110.32 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.491 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -114.17 -10.77 13.15 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.94 -44.39 9.93 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.162 -1.199 . . . . 0.0 110.232 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.63 -16.64 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.365 -0.834 . . . . 0.0 110.4 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.52 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -68.64 -53.29 16.6 Favored Pre-proline 0 N--CA 1.494 1.757 0 O-C-N 121.147 -0.971 . . . . 0.0 110.416 -179.885 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.52 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 26.5 Cg_exo -57.18 -28.84 81.15 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 123.392 1.207 . . . . 0.0 110.198 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.3 tp -68.2 -55.22 13.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.47 -0.769 . . . . 0.0 109.87 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.05 -36.14 70.15 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.294 -0.879 . . . . 0.0 109.862 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.46 -43.11 86.42 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.561 -0.712 . . . . 0.0 109.688 179.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.86 -26.2 71.07 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.73 -43.7 53.67 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.43 -1.041 . . . . 0.0 109.461 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 84.6 mt -69.25 -19.78 63.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.431 -0.793 . . . . 0.0 109.856 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.462 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 35.5 ttpt -81.11 -45.18 16.85 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 0.0 109.996 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -67.01 -13.19 61.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.392 -0.817 . . . . 0.0 110.169 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.889 ' HG ' HG23 ' A' ' 18' ' ' ILE . 13.6 tp -72.69 -60.49 2.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.283 -0.886 . . . . 0.0 110.004 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.889 HG23 ' HG ' ' A' ' 17' ' ' LEU . 29.4 pt -136.14 24.79 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.341 -0.849 . . . . 0.0 110.239 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.462 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 9.8 mttt -133.04 12.18 4.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.321 -0.862 . . . . 0.0 110.339 -179.367 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.321 0 O-C-N 119.699 -1.875 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 16.0 t70 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.211 0.529 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.603 ' O ' HG23 ' A' ' 2' ' ' ILE . 4.5 tp -153.75 57.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.285 -0.885 . . . . 0.0 110.134 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.444 ' HA ' HG22 ' A' ' 6' ' ' ILE . 26.6 m-85 -125.76 -30.56 3.02 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.34 -0.85 . . . . 0.0 110.333 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.478 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -70.99 -19.58 77.21 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.34 -40.76 12.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.182 -1.187 . . . . 0.0 110.341 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.444 HG22 ' HA ' ' A' ' 3' ' ' PHE . 3.5 tt -79.09 -10.55 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.378 -0.826 . . . . 0.0 110.578 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.523 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -76.11 -54.1 2.11 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.113 -0.992 . . . . 0.0 110.191 -179.945 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.523 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 37.7 Cg_exo -55.46 -26.83 55.84 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 O-C-N 123.375 1.197 . . . . 0.0 110.317 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.57 -56.3 7.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.378 -0.826 . . . . 0.0 110.108 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.84 -33.02 69.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.41 -0.807 . . . . 0.0 109.856 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 95.1 mt -69.68 -39.83 76.76 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.494 -0.754 . . . . 0.0 109.715 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.77 -25.02 74.22 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.196 -1.561 . . . . 0.0 109.196 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -77.12 -40.7 44.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.382 -1.069 . . . . 0.0 109.529 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 92.2 mt -76.02 -15.04 60.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.522 -0.736 . . . . 0.0 110.078 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.443 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -77.99 -50.67 11.69 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.363 -0.835 . . . . 0.0 110.172 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -64.69 -11.91 40.89 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.337 -0.852 . . . . 0.0 110.227 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.88 ' HG ' HG23 ' A' ' 18' ' ' ILE . 11.3 tp -72.68 -59.03 2.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 110.023 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.88 HG23 ' HG ' ' A' ' 17' ' ' LEU . 29.1 pt -137.9 22.77 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.35 -0.844 . . . . 0.0 110.21 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.443 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 11.0 mtmt -128.77 52.5 1.93 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.33 -0.856 . . . . 0.0 110.223 -179.293 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.361 0 O-C-N 119.843 -1.786 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.478 ' HB2' ' CE2' ' A' ' 3' ' ' PHE . 11.0 p-10 . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 121.244 0.545 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 47.9 mm -124.06 93.42 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.111 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.478 ' CE2' ' HB2' ' A' ' 1' ' ' ASP . 12.1 m-85 -126.1 1.37 7.2 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.3 -0.875 . . . . 0.0 110.485 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.407 ' O ' ' HD3' ' A' ' 8' ' ' PRO . . . -113.52 -33.0 1.99 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 -27.59 60.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -1.063 . . . . 0.0 110.393 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.1 tt -78.95 -1.96 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.606 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.559 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -85.08 -54.76 0.43 Allowed Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.187 -0.946 . . . . 0.0 110.115 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.559 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 27.5 Cg_exo -57.0 -27.98 76.18 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.499 1.263 . . . . 0.0 110.193 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.9 tp -68.15 -55.73 11.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.42 -0.8 . . . . 0.0 110.025 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.15 -35.56 69.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.285 -0.884 . . . . 0.0 110.015 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 91.6 mt -68.05 -41.77 81.54 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.467 -0.771 . . . . 0.0 109.893 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.32 -24.68 73.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -77.0 -39.21 51.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.416 -1.049 . . . . 0.0 109.395 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.5 mt -70.08 -17.82 63.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.56 -0.713 . . . . 0.0 110.029 179.452 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.448 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 1.2 ttpt -82.62 -44.57 15.63 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.296 -0.878 . . . . 0.0 110.207 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -71.76 -6.19 39.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.329 -0.857 . . . . 0.0 110.086 179.445 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.83 ' HG ' HG23 ' A' ' 18' ' ' ILE . 9.0 tp -78.95 -57.92 3.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.317 -0.864 . . . . 0.0 109.95 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.83 HG23 ' HG ' ' A' ' 17' ' ' LEU . 28.0 pt -138.19 22.8 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.322 -0.861 . . . . 0.0 110.192 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.448 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.6 OUTLIER -130.99 50.07 2.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 -179.425 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.369 0 O-C-N 119.86 -1.775 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.498 ' OD1' HD12 ' A' ' 2' ' ' ILE . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.148 0.499 . . . . 0.0 110.081 . . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.617 ' O ' HG22 ' A' ' 2' ' ' ILE . 5.2 mp -94.69 45.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.278 -0.889 . . . . 0.0 110.24 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.451 ' CE1' ' CB ' ' A' ' 1' ' ' ASP . 24.8 m-85 -95.05 90.86 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.274 -0.891 . . . . 0.0 110.112 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.474 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . 146.17 -30.2 1.62 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.93 -33.12 13.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.431 -1.041 . . . . 0.0 110.021 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.0 tt -70.3 -12.08 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.483 -0.761 . . . . 0.0 110.53 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.527 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -86.27 -56.95 0.35 Allowed Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.164 -0.96 . . . . 0.0 110.35 -179.876 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.527 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 39.2 Cg_exo -51.8 -27.16 26.14 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.31 1.163 . . . . 0.0 110.46 179.256 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -66.79 -57.28 7.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.377 -0.827 . . . . 0.0 110.031 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.22 -36.9 71.45 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.329 -0.857 . . . . 0.0 110.043 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 94.7 mt -64.67 -42.2 95.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.567 -0.708 . . . . 0.0 109.815 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.03 -23.23 76.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.72 -41.16 54.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.378 -1.072 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 49.7 mt -69.93 -19.94 63.36 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.429 -0.795 . . . . 0.0 109.747 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.46 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 25.8 ttpt -81.24 -41.13 22.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.31 -0.869 . . . . 0.0 109.913 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -73.18 -5.69 40.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.331 -0.856 . . . . 0.0 110.08 179.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.826 ' HG ' HG23 ' A' ' 18' ' ' ILE . 5.7 tp -80.67 -56.68 3.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.323 -0.861 . . . . 0.0 109.909 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.826 HG23 ' HG ' ' A' ' 17' ' ' LEU . 26.4 pt -137.29 17.04 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.35 -0.844 . . . . 0.0 110.416 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -125.29 -157.03 0.76 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.261 -0.899 . . . . 0.0 110.091 -179.636 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.331 0 O-C-N 119.805 -1.81 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.228 0.537 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.59 ' O ' HG23 ' A' ' 2' ' ' ILE . 2.1 tp -157.95 68.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.382 -0.824 . . . . 0.0 110.083 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.414 ' CD1' ' O ' ' A' ' 2' ' ' ILE . 31.9 m-85 -138.09 -43.92 0.51 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.332 -0.855 . . . . 0.0 110.187 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -109.68 10.33 32.55 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.33 -50.32 5.71 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.255 -1.144 . . . . 0.0 110.109 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.9 tt -71.58 -22.25 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.85 . . . . 0.0 110.156 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.535 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 m0 -63.74 -58.36 15.35 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.385 -0.822 . . . . 0.0 110.413 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 4.0 Cg_endo -54.56 -36.25 88.4 Favored 'Trans proline' 0 C--N 1.315 -1.222 0 O-C-N 123.426 1.224 . . . . 0.0 111.008 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.0 tt -68.4 -54.5 16.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -37.74 71.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.145 -0.972 . . . . 0.0 110.077 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 61.6 mt -67.32 -40.98 85.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.619 -0.676 . . . . 0.0 109.751 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.28 -25.45 72.41 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.68 -41.44 45.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.309 -1.113 . . . . 0.0 109.592 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 90.9 mt -74.99 -15.76 60.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.495 -0.753 . . . . 0.0 110.094 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.423 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -83.58 -50.73 7.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.87 . . . . 0.0 110.183 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -65.18 -13.3 57.87 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.371 -0.831 . . . . 0.0 110.188 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.905 ' HG ' HG23 ' A' ' 18' ' ' ILE . 13.5 tp -72.16 -59.5 2.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 110.088 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.905 HG23 ' HG ' ' A' ' 17' ' ' LEU . 29.5 pt -137.25 27.08 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.286 -0.884 . . . . 0.0 110.178 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.423 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.7 OUTLIER -134.79 48.69 2.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.326 -0.859 . . . . 0.0 110.205 -179.241 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.383 0 O-C-N 119.853 -1.779 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.227 0.537 . . . . 0.0 110.187 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.573 ' O ' HG23 ' A' ' 2' ' ' ILE . 3.8 tt -149.72 64.68 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.322 -0.861 . . . . 0.0 110.088 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -134.32 -43.83 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.402 -0.811 . . . . 0.0 109.997 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.477 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -76.95 -17.46 79.8 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.94 -40.14 14.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.245 -1.15 . . . . 0.0 110.287 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.1 tp -80.06 -11.89 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -0.85 . . . . 0.0 110.385 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.537 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -72.95 -54.12 4.75 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.181 -0.949 . . . . 0.0 110.316 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.537 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 25.2 Cg_exo -56.94 -27.85 74.98 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.4 1.211 . . . . 0.0 110.264 179.433 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -69.87 -52.27 26.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.465 -0.772 . . . . 0.0 110.057 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.95 -31.69 71.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.35 -0.844 . . . . 0.0 110.003 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 98.4 mt -73.11 -38.92 66.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.436 -0.79 . . . . 0.0 109.89 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.28 -23.08 78.46 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.37 -40.85 29.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.295 -1.12 . . . . 0.0 109.458 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.1 mt -75.9 -15.64 60.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.475 -0.766 . . . . 0.0 110.171 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.419 ' HA ' ' CG ' ' A' ' 19' ' ' LYS . 35.9 ttpt -78.88 -52.48 8.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.188 -0.945 . . . . 0.0 110.098 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -65.43 -12.13 49.44 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.257 -0.902 . . . . 0.0 110.225 179.448 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.909 ' HG ' HG23 ' A' ' 18' ' ' ILE . 10.4 tp -73.96 -58.39 3.33 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.307 -0.871 . . . . 0.0 110.057 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.909 HG23 ' HG ' ' A' ' 17' ' ' LEU . 32.2 pt -137.29 25.59 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.327 -0.858 . . . . 0.0 110.34 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.419 ' CG ' ' HA ' ' A' ' 15' ' ' LYS . 7.0 mtpt -132.78 24.27 4.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.174 -179.411 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.295 0 O-C-N 119.775 -1.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 24.2 p30 . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 121.207 0.527 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.1 mm -114.96 -17.44 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.371 -0.83 . . . . 0.0 110.458 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -109.76 -13.48 14.48 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.316 -0.865 . . . . 0.0 110.423 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.484 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -113.55 2.94 24.85 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.14 -43.23 10.01 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.11 -1.229 . . . . 0.0 110.259 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -78.73 -15.09 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 110.468 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.524 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -71.7 -54.37 6.48 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.117 -0.989 . . . . 0.0 110.385 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 38.9 Cg_exo -54.89 -27.36 53.14 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.387 1.204 . . . . 0.0 110.432 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.15 -58.56 4.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.445 -0.784 . . . . 0.0 110.252 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.01 -37.46 69.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.26 -0.9 . . . . 0.0 110.078 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.4 mt -65.73 -41.22 92.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.527 -0.733 . . . . 0.0 109.856 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.56 -24.49 73.89 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.23 -40.76 51.29 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.359 -1.083 . . . . 0.0 109.698 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.0 mt -76.49 -14.9 60.01 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.445 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.5 OUTLIER -76.85 -48.86 17.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.197 -0.939 . . . . 0.0 110.185 -179.946 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -64.94 -13.52 57.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.284 -0.885 . . . . 0.0 110.171 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.896 ' HG ' HG23 ' A' ' 18' ' ' ILE . 13.8 tp -71.08 -60.5 2.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.864 . . . . 0.0 110.007 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.896 HG23 ' HG ' ' A' ' 17' ' ' LEU . 30.3 pt -136.85 24.12 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.337 -0.852 . . . . 0.0 110.106 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.445 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.8 OUTLIER -131.18 24.55 4.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.372 -0.83 . . . . 0.0 110.195 -179.368 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.355 0 O-C-N 119.894 -1.754 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.3 t70 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.126 0.489 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 2' ' ' ILE . 83.5 mt -134.86 10.44 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 110.397 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -126.93 3.06 6.59 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.305 -0.872 . . . . 0.0 110.262 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.47 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -113.46 -22.38 5.49 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.17 -35.94 15.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.218 -1.166 . . . . 0.0 110.259 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.5 tt -79.02 -7.31 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.378 -0.826 . . . . 0.0 110.614 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.545 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -82.03 -53.83 0.67 Allowed Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.104 -0.997 . . . . 0.0 110.301 -179.929 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.545 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 34.5 Cg_exo -56.62 -26.54 65.38 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.45 1.237 . . . . 0.0 110.244 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.4 tp -70.31 -64.38 0.9 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.551 -0.718 . . . . 0.0 110.308 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.47 -32.65 62.99 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.278 -0.889 . . . . 0.0 110.13 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 67.8 mt -69.37 -38.58 78.12 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.429 -0.795 . . . . 0.0 109.875 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.4 -23.81 77.21 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.26 -42.69 44.86 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.441 -1.035 . . . . 0.0 109.492 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 91.9 mt -68.32 -20.53 64.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.578 -0.701 . . . . 0.0 109.903 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.452 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -87.4 -30.44 20.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.769 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -81.84 1.12 36.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.462 -0.774 . . . . 0.0 110.014 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.841 ' HG ' HG23 ' A' ' 18' ' ' ILE . 4.3 tp -91.31 -56.57 3.09 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.279 -0.888 . . . . 0.0 109.901 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.841 HG23 ' HG ' ' A' ' 17' ' ' LEU . 26.3 pt -136.27 27.31 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.297 -0.877 . . . . 0.0 110.366 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.452 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 13.2 mttt -137.38 173.59 11.5 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.281 -0.887 . . . . 0.0 110.128 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.34 0 O-C-N 119.786 -1.821 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.448 ' HB3' ' CE2' ' A' ' 3' ' ' PHE . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.111 0.482 . . . . 0.0 110.153 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 12.3 mt -79.08 76.35 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 110.121 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.448 ' CE2' ' HB3' ' A' ' 1' ' ' ASP . 36.4 m-85 -120.74 18.59 11.9 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.323 -0.861 . . . . 0.0 110.344 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.408 ' O ' ' HD3' ' A' ' 8' ' ' PRO . . . -122.35 -38.88 0.57 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -76.81 -30.61 56.49 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.36 -1.082 . . . . 0.0 110.264 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -78.38 -5.23 7.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.395 -0.816 . . . . 0.0 110.443 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.548 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -79.54 -55.54 0.86 Allowed Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.137 -0.977 . . . . 0.0 110.102 -179.998 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.548 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 32.2 Cg_exo -55.65 -27.76 62.41 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 O-C-N 123.382 1.201 . . . . 0.0 110.271 179.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.97 -59.24 3.04 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.411 -0.805 . . . . 0.0 110.145 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.85 -33.49 66.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.306 -0.871 . . . . 0.0 109.972 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 65.4 mt -69.11 -40.63 78.22 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.468 -0.77 . . . . 0.0 109.811 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.91 -24.16 75.76 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.88 -42.66 48.57 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.382 -1.069 . . . . 0.0 109.49 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.7 mt -69.97 -19.61 63.35 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.503 -0.748 . . . . 0.0 109.925 179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.407 ' HA ' ' CG ' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -77.42 -50.06 13.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.274 -0.891 . . . . 0.0 109.977 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -64.8 -14.0 57.55 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.327 -0.858 . . . . 0.0 110.0 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.909 ' HG ' HG23 ' A' ' 18' ' ' ILE . 16.7 tp -70.12 -60.62 2.18 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.316 -0.865 . . . . 0.0 109.983 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.909 HG23 ' HG ' ' A' ' 17' ' ' LEU . 31.0 pt -137.04 26.51 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.331 -0.856 . . . . 0.0 110.042 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.407 ' CG ' ' HA ' ' A' ' 15' ' ' LYS . 7.9 mttm -134.03 174.35 10.58 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.343 -0.848 . . . . 0.0 110.142 -179.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.349 0 O-C-N 119.816 -1.803 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 121.159 0.504 . . . . 0.0 110.254 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 91.3 mt -67.03 -27.37 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.375 -0.828 . . . . 0.0 110.135 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 25.0 p90 -105.06 30.05 5.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.417 -0.802 . . . . 0.0 109.981 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -145.87 -37.79 0.06 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.17 -30.71 27.59 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.202 -1.175 . . . . 0.0 110.347 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -78.21 -3.56 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.381 -0.825 . . . . 0.0 110.592 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.553 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -85.61 -54.58 0.42 Allowed Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.12 -0.988 . . . . 0.0 110.281 -179.794 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.553 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 23.7 Cg_exo -58.68 -27.88 84.62 Favored 'Trans proline' 0 C--N 1.313 -1.305 0 O-C-N 123.432 1.227 . . . . 0.0 110.297 179.555 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.9 tp -72.18 -59.11 2.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.417 -0.802 . . . . 0.0 110.33 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.76 -32.54 65.7 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.342 -0.849 . . . . 0.0 110.221 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 96.4 mt -72.49 -38.68 68.08 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.443 -0.786 . . . . 0.0 109.996 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.77 -23.19 78.08 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.7 -42.16 29.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.391 -1.064 . . . . 0.0 109.598 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.2 mt -75.9 -16.98 59.94 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.556 -0.715 . . . . 0.0 110.021 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.447 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 14.5 ttpt -82.21 -46.36 13.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.223 -0.923 . . . . 0.0 110.073 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -66.09 -13.57 60.28 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.345 -0.847 . . . . 0.0 110.149 179.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.906 ' HG ' HG23 ' A' ' 18' ' ' ILE . 15.1 tp -72.11 -60.86 2.02 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.871 . . . . 0.0 110.006 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.906 HG23 ' HG ' ' A' ' 17' ' ' LEU . 32.0 pt -136.34 26.76 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.236 -0.915 . . . . 0.0 110.154 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 10.9 mttm -134.57 100.39 4.63 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.184 -179.398 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.277 0 O-C-N 119.819 -1.801 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.2 t0 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.2 0.524 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.508 ' O ' HG23 ' A' ' 2' ' ' ILE . 1.0 OUTLIER -141.26 55.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.34 -0.85 . . . . 0.0 109.963 179.936 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 13.0 m-85 -126.24 10.42 7.43 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.435 -0.791 . . . . 0.0 110.32 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.491 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -114.17 -10.77 13.15 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.94 -44.39 9.93 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.162 -1.199 . . . . 0.0 110.232 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.63 -16.64 12.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.365 -0.834 . . . . 0.0 110.4 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.52 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -68.64 -53.29 16.6 Favored Pre-proline 0 N--CA 1.494 1.757 0 O-C-N 121.147 -0.971 . . . . 0.0 110.416 -179.885 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.52 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 26.5 Cg_exo -57.18 -28.84 81.15 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 O-C-N 123.392 1.207 . . . . 0.0 110.198 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.3 tp -68.2 -55.22 13.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.47 -0.769 . . . . 0.0 109.87 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.05 -36.14 70.15 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.294 -0.879 . . . . 0.0 109.862 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.46 -43.11 86.42 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.561 -0.712 . . . . 0.0 109.688 179.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.86 -26.2 71.07 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -74.73 -43.7 53.67 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.43 -1.041 . . . . 0.0 109.461 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 84.6 mt -69.25 -19.78 63.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.431 -0.793 . . . . 0.0 109.856 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.462 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 35.5 ttpt -81.11 -45.18 16.85 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.263 -0.898 . . . . 0.0 109.996 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.9 t30 -67.01 -13.19 61.67 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.392 -0.817 . . . . 0.0 110.169 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.889 ' HG ' HG23 ' A' ' 18' ' ' ILE . 13.6 tp -72.69 -60.49 2.21 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.283 -0.886 . . . . 0.0 110.004 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.889 HG23 ' HG ' ' A' ' 17' ' ' LEU . 29.4 pt -136.14 24.79 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.341 -0.849 . . . . 0.0 110.239 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.462 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 9.8 mttt -133.04 12.18 4.27 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.321 -0.862 . . . . 0.0 110.339 -179.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.321 0 O-C-N 119.699 -1.875 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 16.0 t70 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.211 0.529 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.603 ' O ' HG23 ' A' ' 2' ' ' ILE . 4.5 tp -153.75 57.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.285 -0.885 . . . . 0.0 110.134 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.444 ' HA ' HG22 ' A' ' 6' ' ' ILE . 26.6 m-85 -125.76 -30.56 3.02 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.34 -0.85 . . . . 0.0 110.333 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.478 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -70.99 -19.58 77.21 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.34 -40.76 12.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.182 -1.187 . . . . 0.0 110.341 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.444 HG22 ' HA ' ' A' ' 3' ' ' PHE . 3.5 tt -79.09 -10.55 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.378 -0.826 . . . . 0.0 110.578 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.523 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.6 OUTLIER -76.11 -54.1 2.11 Favored Pre-proline 0 N--CA 1.493 1.683 0 O-C-N 121.113 -0.992 . . . . 0.0 110.191 -179.945 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.523 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 37.7 Cg_exo -55.46 -26.83 55.84 Favored 'Trans proline' 0 C--N 1.314 -1.266 0 O-C-N 123.375 1.197 . . . . 0.0 110.317 179.326 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.57 -56.3 7.72 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.378 -0.826 . . . . 0.0 110.108 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -58.84 -33.02 69.95 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.41 -0.807 . . . . 0.0 109.856 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 95.1 mt -69.68 -39.83 76.76 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.494 -0.754 . . . . 0.0 109.715 179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.77 -25.02 74.22 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.196 -1.561 . . . . 0.0 109.196 179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -77.12 -40.7 44.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.382 -1.069 . . . . 0.0 109.529 179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 92.2 mt -76.02 -15.04 60.21 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.522 -0.736 . . . . 0.0 110.078 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.443 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -77.99 -50.67 11.69 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.363 -0.835 . . . . 0.0 110.172 -179.967 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -64.69 -11.91 40.89 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.337 -0.852 . . . . 0.0 110.227 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.88 ' HG ' HG23 ' A' ' 18' ' ' ILE . 11.3 tp -72.68 -59.03 2.92 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 110.023 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.88 HG23 ' HG ' ' A' ' 17' ' ' LEU . 29.1 pt -137.9 22.77 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.35 -0.844 . . . . 0.0 110.21 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.443 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 11.0 mtmt -128.77 52.5 1.93 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.33 -0.856 . . . . 0.0 110.223 -179.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.361 0 O-C-N 119.843 -1.786 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.478 ' HB2' ' CE2' ' A' ' 3' ' ' PHE . 11.0 p-10 . . . . . 0 N--CA 1.492 1.66 0 CA-C-O 121.244 0.545 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 47.9 mm -124.06 93.42 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.111 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.478 ' CE2' ' HB2' ' A' ' 1' ' ' ASP . 12.1 m-85 -126.1 1.37 7.2 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.3 -0.875 . . . . 0.0 110.485 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.407 ' O ' ' HD3' ' A' ' 8' ' ' PRO . . . -113.52 -33.0 1.99 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 -27.59 60.49 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.393 -1.063 . . . . 0.0 110.393 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 14.1 tt -78.95 -1.96 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.41 -0.806 . . . . 0.0 110.606 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.559 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.2 OUTLIER -85.08 -54.76 0.43 Allowed Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.187 -0.946 . . . . 0.0 110.115 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.559 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 27.5 Cg_exo -57.0 -27.98 76.18 Favored 'Trans proline' 0 C--N 1.314 -1.282 0 O-C-N 123.499 1.263 . . . . 0.0 110.193 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.9 tp -68.15 -55.73 11.32 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.42 -0.8 . . . . 0.0 110.025 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.15 -35.56 69.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.285 -0.884 . . . . 0.0 110.015 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 91.6 mt -68.05 -41.77 81.54 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.467 -0.771 . . . . 0.0 109.893 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.32 -24.68 73.61 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -77.0 -39.21 51.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.416 -1.049 . . . . 0.0 109.395 179.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 96.5 mt -70.08 -17.82 63.24 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.56 -0.713 . . . . 0.0 110.029 179.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.448 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 1.2 ttpt -82.62 -44.57 15.63 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.296 -0.878 . . . . 0.0 110.207 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -71.76 -6.19 39.58 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.329 -0.857 . . . . 0.0 110.086 179.445 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.83 ' HG ' HG23 ' A' ' 18' ' ' ILE . 9.0 tp -78.95 -57.92 3.5 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.317 -0.864 . . . . 0.0 109.95 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.83 HG23 ' HG ' ' A' ' 17' ' ' LEU . 28.0 pt -138.19 22.8 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.322 -0.861 . . . . 0.0 110.192 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.448 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.6 OUTLIER -130.99 50.07 2.26 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.337 -0.852 . . . . 0.0 110.207 -179.425 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.369 0 O-C-N 119.86 -1.775 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.498 ' OD1' HD12 ' A' ' 2' ' ' ILE . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 121.148 0.499 . . . . 0.0 110.081 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.617 ' O ' HG22 ' A' ' 2' ' ' ILE . 5.2 mp -94.69 45.14 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.278 -0.889 . . . . 0.0 110.24 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.451 ' CE1' ' CB ' ' A' ' 1' ' ' ASP . 24.8 m-85 -95.05 90.86 6.09 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.274 -0.891 . . . . 0.0 110.112 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.474 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . 146.17 -30.2 1.62 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -93.93 -33.12 13.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.431 -1.041 . . . . 0.0 110.021 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 15.0 tt -70.3 -12.08 15.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.483 -0.761 . . . . 0.0 110.53 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.527 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 1.0 OUTLIER -86.27 -56.95 0.35 Allowed Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.164 -0.96 . . . . 0.0 110.35 -179.876 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.527 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 39.2 Cg_exo -51.8 -27.16 26.14 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 O-C-N 123.31 1.163 . . . . 0.0 110.46 179.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -66.79 -57.28 7.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.377 -0.827 . . . . 0.0 110.031 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -57.22 -36.9 71.45 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.329 -0.857 . . . . 0.0 110.043 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 94.7 mt -64.67 -42.2 95.54 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.567 -0.708 . . . . 0.0 109.815 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -69.03 -23.23 76.11 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.349 -1.5 . . . . 0.0 109.349 179.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -75.72 -41.16 54.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.378 -1.072 . . . . 0.0 109.546 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 49.7 mt -69.93 -19.94 63.36 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.429 -0.795 . . . . 0.0 109.747 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.46 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 25.8 ttpt -81.24 -41.13 22.71 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.31 -0.869 . . . . 0.0 109.913 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -73.18 -5.69 40.91 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.331 -0.856 . . . . 0.0 110.08 179.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.826 ' HG ' HG23 ' A' ' 18' ' ' ILE . 5.7 tp -80.67 -56.68 3.99 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.323 -0.861 . . . . 0.0 109.909 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.826 HG23 ' HG ' ' A' ' 17' ' ' LEU . 26.4 pt -137.29 17.04 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.35 -0.844 . . . . 0.0 110.416 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.0 OUTLIER -125.29 -157.03 0.76 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.261 -0.899 . . . . 0.0 110.091 -179.636 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.331 0 O-C-N 119.805 -1.81 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.228 0.537 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.59 ' O ' HG23 ' A' ' 2' ' ' ILE . 2.1 tp -157.95 68.16 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.382 -0.824 . . . . 0.0 110.083 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.414 ' CD1' ' O ' ' A' ' 2' ' ' ILE . 31.9 m-85 -138.09 -43.92 0.51 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.332 -0.855 . . . . 0.0 110.187 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -109.68 10.33 32.55 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.33 -50.32 5.71 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.255 -1.144 . . . . 0.0 110.109 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.9 tt -71.58 -22.25 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.85 . . . . 0.0 110.156 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.535 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 m0 -63.74 -58.36 15.35 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.385 -0.822 . . . . 0.0 110.413 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 7' ' ' TRP . 4.0 Cg_endo -54.56 -36.25 88.4 Favored 'Trans proline' 0 C--N 1.315 -1.222 0 O-C-N 123.426 1.224 . . . . 0.0 111.008 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.0 tt -68.4 -54.5 16.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.96 -37.74 71.99 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.145 -0.972 . . . . 0.0 110.077 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 61.6 mt -67.32 -40.98 85.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.619 -0.676 . . . . 0.0 109.751 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.28 -25.45 72.41 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.68 -41.44 45.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.309 -1.113 . . . . 0.0 109.592 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 90.9 mt -74.99 -15.76 60.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.495 -0.753 . . . . 0.0 110.094 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.423 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -83.58 -50.73 7.95 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.87 . . . . 0.0 110.183 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -65.18 -13.3 57.87 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.371 -0.831 . . . . 0.0 110.188 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.905 ' HG ' HG23 ' A' ' 18' ' ' ILE . 13.5 tp -72.16 -59.5 2.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 110.088 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.905 HG23 ' HG ' ' A' ' 17' ' ' LEU . 29.5 pt -137.25 27.08 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.286 -0.884 . . . . 0.0 110.178 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.423 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.7 OUTLIER -134.79 48.69 2.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.326 -0.859 . . . . 0.0 110.205 -179.241 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.383 0 O-C-N 119.853 -1.779 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.227 0.537 . . . . 0.0 110.187 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.573 ' O ' HG23 ' A' ' 2' ' ' ILE . 3.8 tt -149.72 64.68 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.322 -0.861 . . . . 0.0 110.088 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -134.32 -43.83 0.77 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.402 -0.811 . . . . 0.0 109.997 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.477 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -76.95 -17.46 79.8 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -87.94 -40.14 14.17 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.245 -1.15 . . . . 0.0 110.287 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.1 tp -80.06 -11.89 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.34 -0.85 . . . . 0.0 110.385 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.537 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -72.95 -54.12 4.75 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.181 -0.949 . . . . 0.0 110.316 -179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.537 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 25.2 Cg_exo -56.94 -27.85 74.98 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.4 1.211 . . . . 0.0 110.264 179.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -69.87 -52.27 26.24 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.465 -0.772 . . . . 0.0 110.057 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -60.95 -31.69 71.24 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.35 -0.844 . . . . 0.0 110.003 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 98.4 mt -73.11 -38.92 66.16 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.436 -0.79 . . . . 0.0 109.89 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -71.28 -23.08 78.46 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.37 -40.85 29.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.295 -1.12 . . . . 0.0 109.458 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 93.1 mt -75.9 -15.64 60.16 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.475 -0.766 . . . . 0.0 110.171 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.419 ' HA ' ' CG ' ' A' ' 19' ' ' LYS . 35.9 ttpt -78.88 -52.48 8.24 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.188 -0.945 . . . . 0.0 110.098 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -65.43 -12.13 49.44 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.257 -0.902 . . . . 0.0 110.225 179.448 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.909 ' HG ' HG23 ' A' ' 18' ' ' ILE . 10.4 tp -73.96 -58.39 3.33 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.307 -0.871 . . . . 0.0 110.057 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.909 HG23 ' HG ' ' A' ' 17' ' ' LEU . 32.2 pt -137.29 25.59 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.327 -0.858 . . . . 0.0 110.34 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.419 ' CG ' ' HA ' ' A' ' 15' ' ' LYS . 7.0 mtpt -132.78 24.27 4.31 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.265 -0.897 . . . . 0.0 110.174 -179.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.295 0 O-C-N 119.775 -1.828 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 24.2 p30 . . . . . 0 N--CA 1.493 1.681 0 CA-C-O 121.207 0.527 . . . . 0.0 110.283 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.1 mm -114.96 -17.44 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.371 -0.83 . . . . 0.0 110.458 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 17.3 p90 -109.76 -13.48 14.48 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.316 -0.865 . . . . 0.0 110.423 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.484 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -113.55 2.94 24.85 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.14 -43.23 10.01 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.11 -1.229 . . . . 0.0 110.259 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -78.73 -15.09 13.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 110.468 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.524 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.4 OUTLIER -71.7 -54.37 6.48 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.117 -0.989 . . . . 0.0 110.385 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 38.9 Cg_exo -54.89 -27.36 53.14 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 O-C-N 123.387 1.204 . . . . 0.0 110.432 179.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.15 -58.56 4.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.445 -0.784 . . . . 0.0 110.252 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -56.01 -37.46 69.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.26 -0.9 . . . . 0.0 110.078 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 45.4 mt -65.73 -41.22 92.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.527 -0.733 . . . . 0.0 109.856 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.56 -24.49 73.89 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.23 -40.76 51.29 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.359 -1.083 . . . . 0.0 109.698 179.741 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 87.0 mt -76.49 -14.9 60.01 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.445 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.5 OUTLIER -76.85 -48.86 17.16 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.197 -0.939 . . . . 0.0 110.185 -179.946 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -64.94 -13.52 57.4 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.284 -0.885 . . . . 0.0 110.171 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.896 ' HG ' HG23 ' A' ' 18' ' ' ILE . 13.8 tp -71.08 -60.5 2.2 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.317 -0.864 . . . . 0.0 110.007 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.896 HG23 ' HG ' ' A' ' 17' ' ' LEU . 30.3 pt -136.85 24.12 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.337 -0.852 . . . . 0.0 110.106 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.445 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 0.8 OUTLIER -131.18 24.55 4.89 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.372 -0.83 . . . . 0.0 110.195 -179.368 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.355 0 O-C-N 119.894 -1.754 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.3 t70 . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.126 0.489 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 2' ' ' ILE . 83.5 mt -134.86 10.44 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 110.397 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -126.93 3.06 6.59 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.305 -0.872 . . . . 0.0 110.262 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.47 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -113.46 -22.38 5.49 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.464 -1.455 . . . . 0.0 109.464 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.17 -35.94 15.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.218 -1.166 . . . . 0.0 110.259 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 4.5 tt -79.02 -7.31 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.378 -0.826 . . . . 0.0 110.614 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.545 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.1 OUTLIER -82.03 -53.83 0.67 Allowed Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.104 -0.997 . . . . 0.0 110.301 -179.929 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.545 ' HD3' ' CB ' ' A' ' 7' ' ' TRP . 34.5 Cg_exo -56.62 -26.54 65.38 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.45 1.237 . . . . 0.0 110.244 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.4 tp -70.31 -64.38 0.9 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.551 -0.718 . . . . 0.0 110.308 -179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -55.47 -32.65 62.99 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.278 -0.889 . . . . 0.0 110.13 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 67.8 mt -69.37 -38.58 78.12 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.429 -0.795 . . . . 0.0 109.875 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -70.4 -23.81 77.21 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.26 -42.69 44.86 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.441 -1.035 . . . . 0.0 109.492 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 91.9 mt -68.32 -20.53 64.75 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.578 -0.701 . . . . 0.0 109.903 179.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.452 ' HA ' ' HB2' ' A' ' 19' ' ' LYS . 0.0 OUTLIER -87.4 -30.44 20.74 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.769 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -81.84 1.12 36.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.462 -0.774 . . . . 0.0 110.014 179.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.841 ' HG ' HG23 ' A' ' 18' ' ' ILE . 4.3 tp -91.31 -56.57 3.09 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.279 -0.888 . . . . 0.0 109.901 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.841 HG23 ' HG ' ' A' ' 17' ' ' LEU . 26.3 pt -136.27 27.31 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.297 -0.877 . . . . 0.0 110.366 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.452 ' HB2' ' HA ' ' A' ' 15' ' ' LYS . 13.2 mttt -137.38 173.59 11.5 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.281 -0.887 . . . . 0.0 110.128 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.34 0 O-C-N 119.786 -1.821 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_